The added-up albumin enhances the diuretic effect of furosemide in patients with hypoalbuminemic chronic kidney disease: a randomized controlled study

BMC Nephrology

Kochawan Boonyawat²  Bunyong Phakdeekitcharoen¹ 

[1]Division of Nephrology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

[2]Internal Medicine, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

关键词: Edema;    Albumin;    Furosemide;    Chronic kidney disease (CKD);   

Others  :  1083119
DOI  :  10.1186/1471-2369-13-92

 received in 2012-06-06, accepted in 2012-08-27,  发布年份 2012

【 摘 要 】

Background

Chronic kidney disease (CKD) with edema is a common clinical problem resulting from defects in water and solute excretion. Furosemide is the drug of choice for treatment. In theory, good perfusion and albumin are required for the furosemide to be secreted at the tubular lumen. Thus, in the situation of low glomerular filtration rate (GFR) and hypoalbuminemia, the efficacy of furosemide alone might be limited. There has been no study to validate the effectiveness of the combination of furosemide and albumin in this condition.

Methods

We conducted a randomized controlled crossover study to compare the efficacy of diuretics between furosemide alone and the combination of furosemide plus albumin in stable hypoalbuminemic CKD patients by measuring urine output and sodium. The baseline urine output/sodium at 6 and 24 hours were recorded. The increment of urine output/sodium after treatment at 6 and 24 hours were calculated by using post-treatment minus baseline urine output/sodium at the corresponding period.

Results

Twenty-four CKD patients (GFR = 31.0 ± 13.8 mL/min) with hypoalbuminemia (2.98 ± 0.30 g/dL) were enrolled. At 6 hours, there were significant differences in the increment of urine volume (0.47 ± 0.40 vs 0.67 ± 0.31 L, P < 0.02) and urine sodium (37.5 ± 29.3 vs 55.0 ± 26.7 mEq, P < 0.01) between treatment with furosemide alone and with furosemide plus albumin. However, at 24 hours, there were no significant differences in the increment of urine volume (0.49 ± 0.47 vs 0.59 ± 0.50 L, P = 0.46) and urine sodium (65.3 ± 47.5 vs 76.1 ± 50.1 mEq, P = 0.32) between the two groups.

Conclusion

The combination of furosemide and albumin has a superior short-term efficacy over furosemide alone in enhancing water and sodium diuresis in hypoalbuminemic CKD patients.

Trial registration

The Australian New Zealand Clinical Trials Registration (ANZCTR12611000480987)

【 授权许可】

   
2012 Phakdeekitcharoen and Boonyawat; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Brater DC: Diuretic therapy. N Engl J Med 1998, 339:387-395.
• [2]Rose BD: Diuretics. Kidney Int 1991, 39:336-352.
• [3]Bleich M, Greger R: Mechanism of action of diuretics. Kidney Int 1997, 59(Suppl):S11-S15.
• [4]Hropot M, Fowler N, Karlmark B, Giebisch G: Tubular action of diuretics: distal effects on electrolyte transport and acidification. Kidney Int 1985, 28:477-489.
• [5]Ponto LL, Schoenwald RD: Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I). Clin Pharmacokinet 1990, 18:381-408.
• [6]Hebert SC: Molecular mechanisms. Semin Nephrol 1999, 19:504-523.
• [7]Brater DC: Resistance to diuretics: emphasis on a pharmacological perspective. Drugs 1981, 22:477-494.
• [8]Pichette V, Geadah D, du Souich P: The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit. Br J Pharmacol 1996, 119:885-890.
• [9]Inoue M, Okajima K, Itoh K, Ando Y, Watanabe N, Yasaka T, Nagase S, Morino Y: Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney Int 1987, 32:198-203.
• [10]Besseghir K, Mosig D, Roch-Ramel F: Facilitation by serum albumin of renal tubular secretion of organic anions. Am J Physiol 1989, 256:F475-F484.
• [11]Rane A, Villeneuve JP, Stone WJ, Nies AS, Wilkinson GR, Branch RA: Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia. Clin Pharmacol Ther 1978, 24:199-207.
• [12]Voelker JR, Cartwright-Brown D, Anderson S, Leinfelder J, Sica DA, Kokko JP, Brater DC: Comparison of loop diuretics in patients with chronic renal insufficiency. Kidney Int 1987, 32:572-578.
• [13]Chennavasin P, Seiwell R, Brater DC, Liang WM: Pharmacodynamic analysis of the furosemide-probenecid interaction in man. Kidney Int 1979, 16:187-195.
• [14]Brater DC: Effects of probenecid on furosemide response. Clin Pharmacol Ther 1978, 24:548-554.
• [15]Rose HJ, Pruitt AW, Dayton PG, McNay JL: Relationship of urinary furosemide excretion rate to natriuretic effect in experimental azotemia. J Pharmacol Exp Ther 1976, 199:490-497.
• [16]Fliser D, Zurbruggen I, Mutschler E, Bischoff I, Nussberger J, Franek E, Ritz E: Coadministration of albumin and furosemide in patients with the nephrotic syndrome. Kidney Int 1999, 55:629-634.
• [17]Na KY, Han JS, Kim YS, Ahn C, Kim S, Lee JS, Bae KS, Jang IJ, Shin SG, Huh W, et al.: Does albumin preinfusion potentiate diuretic action of furosemide in patients with nephrotic syndrome? J Korean Med Sci 2001, 16:448-454.
• [18]Akcicek F, Yalniz T, Basci A, Ok E, Mees EJ: Diuretic effect of frusemide in patients with nephrotic syndrome: is it potentiated by intravenous albumin? BMJ 1995, 310:162-163.
• [19]Gentilini P, Casini-Raggi V, Di Fiore G, Romanelli RG, Buzzelli G, Pinzani M, La Villa G, Laffi G: Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol 1999, 30:639-645.
• [20]Chalasani N, Gorski JC, Horlander JC Sr, Craven R, Hoen H, Maya J, Brater DC: Effects of albumin/furosemide mixtures on responses to furosemide in hypoalbuminemic patients. J Am Soc Nephrol 2001, 12:1010-1016.
• [21]Brater DC, Chalasani N, Gorski JC, Horlander JC Sr, Craven R, Hoen H, Maya J: Effect of albumin-furosemide mixtures on response to furosemide in cirrhotic patients with ascites. Trans Am Clin Climatol Assoc 2001, 112:108-115. discussion 116
• [22]Fujita A, Kitayama M, Hirota K: Anaphylactoid shock in a patient following 5% human serum albumin infusion during off-pump coronary artery bypass grafting. J Anesth 2007, 21:396-398.
• [23]Stafford CT, Lobel SA, Fruge BC, Moffitt JE, Hoff RG, Fadel HE: Anaphylaxis to human serum albumin. Ann Allergy 1988, 61:85-88.
• [24]Sjostrom PA, Odlind BG, Beermann BA, Karlberg BE: Pharmacokinetics and effects of frusemide in patients with the nephrotic syndrome. Eur J Clin Pharmacol 1989, 37:173-180.
• [25]Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC: Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 1995, 57:601-609.
• [26]Brater DC, Chennavasin P, Day B, Burdette A, Anderson S: Bumetanide and furosemide. Clin Pharmacol Ther 1983, 34:207-213.
• [27]Wilcox CS, Guzman NJ, Mitch WE, Kelly RA, Maroni BJ, Souney PF, Rayment CM, Braun L, Colucci R, Loon NR: Na+, K+, and BP homeostasis in man during furosemide: effects of prazosin and captopril. Kidney Int 1987, 31:135-141.
• [28]Kirchner KA, Voelker JR, Brater DC: Intratubular albumin blunts the response to furosemide-A mechanism for diuretic resistance in the nephrotic syndrome. J Pharmacol Exp Ther 1990, 252:1097-1101.
• [29]Elwell RJ, Spencer AP, Eisele G: Combined furosemide and human albumin treatment for diuretic-resistant edema. Ann Pharmacother 2003, 37:695-700.
• [30]Hebert SC: Journal Ar, ticle: Molecular mechanisms. Semin Nephrol 1999, 19:504-523.
• [31]De Bruyne LK: Mechanisms and management of diuretic resistance in congestive heart failure. Postgrad Med J 2003, 79:268-271.
• [32]Ellison DH: Diuretic drugs and the treatment of edema: from clinic to bench and back again. Am J Kidney Dis 1994, 23:623-643.
• [33]Freis ED: The efficacy and safety of diuretics in treating hypertension. Ann Intern Med 1995, 122:223-226.